TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Mutual Interactions Between Absence Epilepsy Seizures and the Integration of Sensory Stimuli

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria :~* Age 2-20 years~* childhood or juvenile absence epilepsy defined by International Ligue Against Epilepsy (ILAE)~* Electroencephalogram (EEG) indicated for clinical follow-up~Non inclusion criteria:~* Visual deficit~* Abnormal Magnetic Resonance Imaging (MRI)~* Medical history of photosensitive epileptic seizures

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Timed repetitive sensory stimulation (Type: EXPERIMENTAL): Timed repetitive sensory stimulation (TRSS) will be applied at the onset or during seizures

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: BIIB023 Long-Term Extension Study in Subjects With Lupus Nephritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Subjects who completed Week 52 of Study 211LE201 (NCT01499355) and did not discontinue BIIB023 or placebo study treatment.~* Subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception for 6 months after their last dose of study treatment.~Key Exclusion Criteria:~* Any significant change in medical history in subjects from Study 211LE201, including laboratory tests or current clinically significant condition that, in the opinion of the Investigator, would have excluded the subjects' participation. The Investigator must re-review the subject's medical fitness for participation and consider any diseases that would preclude treatment under this protocol.~* Subjects from Study 211LE201 who discontinued BIIB023 or placebo treatment prior to Week 52 of Study 211LE201.~* Female subjects considering becoming pregnant while in the study, currently pregnant, or breast feeding.~* Unwillingness or inability to comply with the requirements of the protocol including the presence of any condition (physical, mental, or social) that is likely to affect the subject's ability to comply with the protocol.~* Other unspecified reasons that, in the opinion of the Investigator or Biogen, makes the subject unsuitable for enrollment.~NOTE: Other Protocol-defined Inclusion/Exclusion Criteria May Apply.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 76 Years
- Healthy Volunteers: f

Study Arms:
- BIIB023 3 mg/kg (Type: EXPERIMENTAL): Participants will receive BIIB023 3 mg/kg IV every 4 weeks through Week 100 plus background therapy including oral steroids (prednisone or equivalent) and mycophenolate mofetil (MMF).
- BIIB023 20 mg/kg (Type: EXPERIMENTAL): Participants will receive BIIB023 20 mg/kg IV every 4 weeks through Week 100 plus background therapy including oral steroids (prednisone or equivalent) and MMF.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Standalone OMNI Surgical System for Open-angle Glaucoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~* Patients aged 30-95 with primary or pigmentary / pseudoexfolliative / juvenile / normal pressure open angle glaucoma or combined mechanism glaucoma.~* An IOP of 10-40 mmHg on maximum tolerated medical therapy who are either progressing, above IOP target, or poorly adherent or tolerant to medical therapy.~* Phakic or pseudophakic eyes and previous laser trabeculoplasty will be included.~Exclusion Criteria:~* Other forms of glaucoma,~* prior incisional glaucoma surgery,~* prior corneal graft (PKP, DALK, DSAEK, DMEK),~* Shafer angle grading \<2 in 2 or more quadrants.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 95 Years
- Healthy Volunteers: None

Study Arms:
- Oen Angle Glaucoma (Type: None): • Patients aged 30-95 with primary or pigmentary / pseudoexfolliative / juvenile / normal pressure open angle glaucoma or combined mechanism glaucoma with IOP of 10-40 mmHg on maximum tolerated medical therapy who are either progressing, above IOP target, or poorly adherent or tolerant to medical therapy. Phakic or pseudophakic eyes and previous laser trabeculoplasty will be included.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Specialized Pacing for Patients With Congenital Heart Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Congenital heart disease~  • Simple, moderate, or complex congenital heart disease~* Adolescent or adult age group (age \>14 and \<65 years)~* Significant sinus node dysfunction~  * Atrial pacing percentage \>70%11~ * Intrinsic dysfunction resulting from congenital lesion or cardiac surgery~ * Secondary sinus node dysfunction due to antiarrhythmic drug therapy~* Existing, fully functional pacemaker or ICD with CLS capability~* Epicardial or transvenous route of pacemaker implantation~Exclusion Criteria:~* Unable to complete cardiopulmonary exercise testing (CPET)~* Contraindication to CPET~* Decreased mental capacity or known psychiatric disorder~* Congestive heart failure, NYHA cass IV~* Total atrial tachyarrhythmia burden \>20%

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- CLS-On (Type: EXPERIMENTAL): Subjects in this arm will be programmed to CLS-on to received closed loop stimulation-based pacing for 3 months, followed by a standard rate response for 3 months.
- CLS-Off (Type: ACTIVE_COMPARATOR): Subjects in this arm, will be placed in a standard rate response for 3 months, followed by CLS-on to received closed loop stimulation-based pacing for 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: WiiMote Game Controller as a Device to Study Movement Disorders

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Men and women, aged 18 or older, with abnormal movements (including tremor, chorea, dystonia, myoclonus, and tic) and normal controls (subjects without abnormal movements).~2. Subjects must be willing and able to comply with study procedures.~3. Patients must be willing and able to give meaningful, written informed consent.~Exclusion Criteria:~1. Significant cognitive impairment which, in the opinion of the Investigator, would interfere with the ability to complete all the tests required in the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control Group (Type: None): Participants with no movement disorders.
- Movement Disorders Participants (Type: None): Participants have a movement disorder

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Flow Rate Impact on Arterial Carbon Dioxide During THRIVE

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients presenting for elective surgery~Exclusion Criteria:~* Age \<18 or \>65 years~* Body Mass Index (BMI) \>35 kg m-2~* American Society of Anesthesiology classification \> 2~* Physical activity level less than 5 metabolic equivalents~* Obstruction of the upper airways~* Known or high clinical suspicion of difficult airway~* Obstructive sleep apnea syndrome~* Increased risk of aspiration~* Pulmonary or cardiac condition resulting in a reduction of physical activity level equivalent to the New York Heart Association class of 2 or higher.~* Any contraindication to high-flow nasal oxygen therapy or hypercapnia~* Pregnancy or breastfeeding~* Allergy to any of the anesthetic agents used in the study~* Inability to comprehend oral or written information.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- THRIVE 40 L/min (Type: ACTIVE_COMPARATOR): 40 L/min with 100% oxygen for 10 minutes.
- THRIVE 100 L/min (Type: EXPERIMENTAL): 100 L/min with 100% oxygen for 10 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Evidence of myeloma according to the criteria of the British Columbia Cancer Agency (for the diagnosis, 2 of the 3 criteria must be met):~  * Evidence of paraprotein in the serum or urine~ * Bone marrow infiltration with plasma cells which represent more than 10% of the nucleated cells~ * Radiologically, at least one osteolytic lesion~* Asymptomatic patients with Stage I (Durie and Salmon) multiple myeloma~Exclusion criteria:~* Patients with more than one osteolytic lesion on conventional skeletal radiography~* Previous treatment with bisphosphonates~* bilirubin \> 2.5 mg/dl~* Abnormal renal function as evidenced by: A calculated creatinine clearance \< 30 ml/minute. Creatinine clearance (CrCl) is calculated using the Cockcroft-Gault formula:~  * CrCl= \[140-age(years)\] x weight(kg)/\[72xserumcreatinine(mg/dL)\] X {0.85 for female patients}~* Patients with other malignant diseases or severe concomitant diseases~* Potentially fertile patients who are not using a reliable and appropriate method of contraception~* Pregnancy or breast-feeding~* Participation in another clinical study with an investigational drug within 12 weeks of study entry~* Current active dental problems including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a current or prior diagnosis of osteonecrosis of the jaw (ONJ), of exposed bone in the mouth, or of slow healing after dental procedures.~* Recent (within 6 weeks) or planned dental or jaw surgery (e.g.. extraction, implants)~Other protocol-defined inclusion and exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zoledronic acid (ZOL446) (Type: EXPERIMENTAL): Participants received intravenous infusion of Zoledronic acid every 4 weeks for 48 weeks, and calcium and Vitamin D daily.
- Control (Type: NO_INTERVENTION): No treatment with study medication.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sunitinib and Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed renal cell carcinoma~  * Primary lesion or metastatic site demonstrating clear cell variant with \< 25% of any other histology~* Radiographically measurable disease by RECIST criteria~* Initiated treatment with sunitinib malate ≤ 6 weeks ago~* No radiographically detectable brain metastases by MRI or CT scan~* HLA-partially matched related donor available, as determined by serologic and/or DNA typing~  * Appropriate HLA match (≥ 2/6 HLA A, B, DR match)~PATIENT CHARACTERISTICS:~* ECOG performance status 0-1~* Absolute neutrophil count \> 1,500/mm³~* Platelet count \> 100,000/mm³~* Total bilirubin ≤ 2.0 times upper limit of normal (ULN)~* AST ≤ 3.0 times ULN~* Calculated creatinine clearance ≥ 40 mL/min~* Cardiac ejection fraction ≥ 50%~* QTc interval \< 500 msec by EKG~* Not pregnant~* Negative pregnancy test~* Fertile patients must use effective contraception~* No known HIV positivity~* None of the following within the past 6 months:~  * Myocardial infarction~ * Severe/unstable angina~ * Coronary/peripheral artery bypass graft~ * Symptomatic congestive heart failure~ * Cerebrovascular accident or transient ischemic attack~ * Pulmonary embolism~* No ongoing ventricular cardiac dysrhythmias ≥ grade 2, according to NCI CTCAE v3.0~* No history of serious ventricular arrhythmia (e.g., ventricular tachycardia \> 3 beats in a row)~* No ongoing atrial fibrillation~* No other malignancies within the past 3 years, other than basal cell skin cancer, squamous cell skin cancer, in situ cervical cancer, or ductal or lobular carcinoma in situ of the breast~* No other concurrent serious illness~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior systemic therapy for metastatic renal cell carcinoma~* No prior immunotherapy~* No prior VEGF-targeted or mTOR-targeted therapies~* No concurrent cytochrome P450 enzyme-inducing antiepileptic drugs (e.g., phenytoin, carbamazepine, or phenobarbital), St. John's wort, ketoconazole, dexamethasone, dysrhythmic drugs (e.g., terfenadine, quinidine, procainamide, sotalol, probucol, bepridil, indapamide, or flecainide), haloperidol, risperidone, rifampin, grapefruit, or grapefruit juice~* No other concurrent investigational anticancer agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Sunitinib plus Irradiated Allogeneic Lymphocytes (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Development of AWZ1066S, a Small Molecule Anti-Wolbachia Candidate Macrofilaricide Drug

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy male and female participants 2 aged 18-65 years 3 BMI 18.0-35.0 kg/m2, maximum weight 100 kg 4 in good health, as determined by: 4a medical history, 4b physical examination, 4c vital signs assessment, 4d 12-lead ECG 4e clinical laboratory evaluations 5 provision of informed consent and abide by study restrictions~Exclusion Criteria:~1. not willing to abide by contraception restrictions~2. donated blood in previous 3 months, plasma previous 7 days, platelets previous 6 weeks~3. consumption \>14 units of alcohol/week~4. tobacco smoking~5. concomitant medication, apart from treatments for mild asthma, eczema, contraception, paracetamol~6. herbal remedies~7. history of anaphylaxis, drug allergy, clinically significant atopic condition as determined by Investigator~8. clinically significant medical history, as determined by the Investigator~9. positive hepatitis, HIV serology~10. live vaccine in previous 3 months, Covid-19 vaccine prior 14 days~11. Participants who, in the opinion of the Investigator, should not participate in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- AWZ1066S (Type: EXPERIMENTAL): AWZ1066S~Part A Cohort A1- 100mg single dose Cohort A2- 200mg single dose Cohort A3- 400mg single dose Cohort A4- 800mg fasted single dose and 800mg fed single dose Cohort A5- 1200mg single dose Cohort A6- 1600mg single dose~The doses for part B will be selected following review of data from Part A. Cohort B1- AWZ1066S once daily for 7 days Cohort B2- AWZ1066S once daily for 7 days Cohort B3- AWZ1066S once daily for 7 days Cohort B4- AWZ1066S once daily for 7 days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo~Cohort A1- equivalent placebo single dose Cohort A2- equivalent placebo single dose Cohort A3- equivalent placebo single dose Cohort A4- equivalent placebo fasted single dose and equivalent placebo fed single dose Cohort A5- equivalent placebo single dose Cohort A6- equivalent placebo single dose~The doses for part B will be selected following review of data from Part A. Cohort B1- equivalent placebo once daily for 7 days Cohort B2- equivalent placebo once daily for 7 days Cohort B3- equivalent placebo once daily for 7 days Cohort B4- equivalent placebo once daily for 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study in Healthy Male Volunteers Investigating the Safety, Absorption and Elimination of Single Doses of GLPG4059

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Male between 18-54 years of age (extremes included), on the date of signing the informed consent form (ICF).~* A body mass index (BMI) between 18-30 kg/m2, inclusive.~* Judged to be in good health by the investigator based upon the results of a medical history, physical examination, vital signs, 12-lead ECG, and fasting clinical laboratory safety tests, available at screening and prior to randomization. ECG and vital signs parameters must be within the normal ranges. Bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) must be no greater than 1.5x upper limit of normal (ULN). Fasting plasma glucose must be \<6.99 mmol/L, fasting defined as no caloric intake for at least 8 hours and hemoglobin A1c (HbA1c) \<6.5% (48 mmol/mol). The test should be performed in a laboratory using a method that is national glycohemoglobin standardization program (NGSP) certified and standardized to the diabetes control and complications trial (DCCT) assay. Other clinical laboratory safety test results must be within the reference ranges or test results that are outside the reference ranges need to be considered not clinically significant in the opinion of the investigator.~This list only contains the key inclusion criteria.~Exclusion Criteria:~* Known hypersensitivity to Investigational Medicinal Product (IMP) ingredients or history of a significant allergic reaction to IMP ingredients as determined by the investigator.~* Positive serology for hepatitis B virus surface antigen (HBsAg) or hepatitis C virus (HCV) or history of hepatitis from any cause with the exception of hepatitis A that was resolved at least 3 months prior to first dosing of the IMP.~This list only contains the key exclusion criteria.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 54 Years
- Healthy Volunteers: t

Study Arms:
- GLPG4059 SAD (Type: EXPERIMENTAL): Single doses of GLPG4059 at up to 6 dose levels in ascending order
- Placebo SAD (Type: PLACEBO_COMPARATOR): Single doses of placebo
- GLPG4059 rBA/FE oral suspension fasted (Type: EXPERIMENTAL): Single dose of GLPG4059 in fasted state
- GLPG4059 rBA/FE tablet fed (Type: EXPERIMENTAL): Single dose of GLPG4059 in fed state
- GLPG4059 rBA/FE tablet fasted (Type: EXPERIMENTAL): Single dose of GLPG4059 in fasted state

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Open vs Laparoscopic Pyloromyotomy for Pyloric Stenosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* clinical diagnosis of infantile hypertrophic pyloric stenosis~Exclusion Criteria:~* Presence of co-existing congenital or chromosomal abnormality~* The need to perform any additional procedure at the time of pylotomyotomy~* Failure to receive informed consent

- Gender: ALL
- Minimum Age: 0 Months
- Maximum Age: 3 Months
- Healthy Volunteers: f

Study Arms:
- laparoscopic pyloromyotomy (Type: EXPERIMENTAL): None
- open pyloromyotomy (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Use of Finasteride to Reduce Hematuria and Hematospermia Following TRUS Prostate Biopsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent prior to the participation in any study related activity.~2. Male subject already identified as requiring TRUS prostate biopsy for unrelated medical reasons.~Exclusion Criteria:~1. Suspected or known liver disease.~2. Suspected or known hematological disorders.~3. Subjects who are candidates for immediate surgery.~4. Known hypersensitivity to any component of the product.

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 5mg finasteride orally, daily for 2 weeks prior to prostate biopsy and one week following prostate biopsy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues